Hospital
Cheshire Medical Center
Cheshire Medical Center was paid $1.30M by Medicaid between Apr 2021 and Nov 2024, across 154 billing codes. Its largest line is 99284, emergency room visit (serious) — 18% of everything it billed.
33Billing provider infoCHESHIRE MEDICAL CENTER
KEENE, NH 03431
KEENE, NH 03431
33aNPI1629181516assigned 08/16/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$1.30M
24GClaims45,371
24DCodes billed154
24AFirst – last monthApr 2021 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in New Hampshire
Rank by total paid#8 of 9
Median peer was paid$10.80M
This provider vs. median0.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 174 | $853.04 | |
| 2022 | 38,949 | $1.08M | |
| 2023 | 3,790 | $136K | |
| 2024incomplete | 2,458 | $82K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 1,575 | 1,395 | $235K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.1% | 531 | 421 | $106K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 7.6% | 1,975 | 1,374 | $99K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 6.7% | 831 | 733 | $87K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 5.0% | 499 | 428 | $65K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.4% | 100 | 66 | $45K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 3.3% | 1,694 | 985 | $43K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.2% | 1,493 | 503 | $42K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.4% | 1,089 | 865 | $32K |
| 71046 | Radiologic examination, chest; 2 views | 2.1% | 487 | 404 | $28K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.9% | 4,806 | 3,989 | $25K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.9% | 81 | 76 | $25K |
142 more codes
| 70450 | Computed tomography, head or brain; without contrast material | 1.7% | 134 | $22K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.4% | 332 | $18K |
| 97161 | 1.4% | 222 | $18K | |
| 80053 | Comprehensive metabolic panel | 1.2% | 2,179 | $16K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.2% | 63 | $16K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.2% | 43 | $16K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 1.2% | 15 | $15K |
| 73630 | 1.1% | 204 | $14K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 211 | $13K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,174 | $13K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 37 | $12K |
| G0378 | Hospital observation service, per hour | <1% | 61 | $12K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 39 | $11K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 288 | $10K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 354 | $10K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 138 | $10K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 109 | $10K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 289 | $9K |
| 73610 | <1% | 135 | $8K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 199 | $8K |
| 73562 | <1% | 101 | $8K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 96 | $8K |
| 71045 | Radiologic examination, chest; single view | <1% | 175 | $7K |
| 80061 | Lipid panel | <1% | 674 | $7K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 341 | $7K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 340 | $7K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,149 | $7K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 217 | $7K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 816 | $6K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 282 | $6K |
| 87800 | <1% | 238 | $5K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 184 | $5K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 219 | $5K |
| 96376 | <1% | 80 | $5K | |
| 87806 | <1% | 250 | $5K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 109 | $4K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 112 | $4K |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,148 | $4K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 173 | $4K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 62 | $4K |
| 73030 | <1% | 60 | $4K | |
| 84702 | <1% | 269 | $3K | |
| 86803 | <1% | 270 | $3K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 135 | $3K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 184 | $3K |
| 73130 | <1% | 60 | $3K | |
| 85027 | <1% | 501 | $3K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 135 | $3K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 102 | $2K |
| 82728 | <1% | 208 | $2K | |
| 72100 | <1% | 28 | $2K | |
| 73110 | <1% | 40 | $2K | |
| 74018 | <1% | 46 | $2K | |
| 84484 | <1% | 266 | $2K | |
| 84439 | <1% | 273 | $2K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 359 | $2K |
| 82607 | <1% | 173 | $2K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 15 | $2K |
| 11721 | <1% | 113 | $2K | |
| 83880 | <1% | 82 | $2K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 84 | $2K |
| 83655 | <1% | 154 | $2K | |
| 80306 | <1% | 166 | $2K | |
| 86850 | <1% | 161 | $2K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 239 | $1K |
| 73100 | <1% | 49 | $1K | |
| 83690 | <1% | 288 | $1K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 82 | $1K |
| 86780 | <1% | 114 | $1K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 48 | $1K |
| 86140 | <1% | 291 | $1K | |
| 83550 | <1% | 172 | $1K | |
| 83735 | <1% | 238 | $1K | |
| 87186 | <1% | 154 | $1K | |
| 80076 | <1% | 181 | $1K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 36 | $1K |
| 82962 | <1% | 295 | $1K | |
| 81001 | <1% | 471 | $1K | |
| 83516 | <1% | 99 | $1K | |
| 84403 | <1% | 47 | $1K | |
| 84146 | <1% | 67 | $981.76 | |
| 87340 | <1% | 120 | $976.99 | |
| 82784 | <1% | 97 | $958.68 | |
| 81025 | <1% | 190 | $910.10 | |
| 82803 | <1% | 49 | $896.65 | |
| 85610 | <1% | 312 | $864.07 | |
| 87430 | <1% | 87 | $854.50 | |
| 83540 | <1% | 172 | $843.99 | |
| 80050 | General health panel | <1% | 104 | $792.32 |
| 82570 | <1% | 176 | $746.95 | |
| 87040 | <1% | 47 | $744.58 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 526 | $741.23 |
| 87070 | <1% | 93 | $689.10 | |
| 83605 | <1% | 88 | $686.29 | |
| 84153 | <1% | 59 | $659.92 | |
| 73140 | <1% | 12 | $648.31 | |
| 86039 | <1% | 75 | $627.44 | |
| 85379 | <1% | 81 | $598.53 | |
| 85652 | <1% | 286 | $584.62 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 15 | $580.70 |
| 86618 | <1% | 49 | $561.49 | |
| 86787 | <1% | 54 | $559.35 | |
| 82043 | <1% | 137 | $551.01 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 24 | $464.03 |
| 86900 | <1% | 166 | $451.38 | |
| 86762 | <1% | 37 | $396.83 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 166 | $383.81 |
| 86901 | <1% | 166 | $378.51 | |
| 81003 | <1% | 283 | $365.18 | |
| 87147 | <1% | 43 | $355.35 | |
| 84460 | <1% | 78 | $329.48 | |
| 87205 | <1% | 89 | $321.98 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 259 | $301.60 |
| 82670 | <1% | 14 | $286.84 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 244 | $255.36 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 224 | $249.68 |
| 82565 | <1% | 65 | $228.04 | |
| 85730 | <1% | 48 | $218.12 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 243 | $209.50 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 15 | $203.52 |
| 86706 | <1% | 20 | $198.57 | |
| 84100 | <1% | 54 | $184.76 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 74 | $162.54 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 272 | $144.16 |
| J2704 | Injection, propofol, 10 mg | <1% | 58 | $140.97 |
| 84450 | <1% | 32 | $129.78 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 57 | $101.80 |
| 82550 | <1% | 16 | $99.64 | |
| 86431 | <1% | 27 | $91.04 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 321 | $89.13 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 199 | $87.67 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 29 | $56.23 |
| 84550 | <1% | 29 | $55.97 | |
| 82950 | <1% | 14 | $52.86 | |
| 82947 | <1% | 15 | $40.08 | |
| 84132 | <1% | 12 | $35.42 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 64 | $25.26 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 13 | $22.85 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 12 | $12.80 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 22 | $12.54 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 27 | $1.52 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 103 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWOOD, GARY (DIRECTOR REVENUE CYCLE INTEGRITY)
| Provider | Location | Paid |
|---|---|---|
| Cheshire Medical Center | Keene, NH | $4.53M |
| Ranch Acres Family Dentistry PC | Tulsa, OK | $129K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.